Companya Study May News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA provides Study May Proceed letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024 SHELTON, Conn., Jan. 3, 2024.

United statesMerck sharpe dohmeJonathan nugentDavid rosenLewish benderBristol myers squibbChristian frederick meyerCompany nasdaqOttawa hospital research instituteOffice of orphan products developmentDrug administrationPrnewswire intensity therapeutics incOntario institute of cancer researchCompanya study mayIntensity therapeutics incInvestigational new drug